A-Bio Secures Major Deal with Novo Nordisk
A-Bio Pharma Pte Ltd (A-Bio) announced that it has entered into a multi-year Master Service Agreement with Novo Nordisk A/S. Under the agreement, Novo Nordisk will engage A-Bio for process development and GMP clinical supply of biologics in its pipeline of biopharmaceutical projects.
"We are delighted by this exciting, multi-product collaboration with Novo Nordisk, a world leader in diabetes care," said Dr George Wang, Managing Director of A-Bio. "Securing yet another international biopharmaceutical company as our long term partner is a substantial step towards strengthening our global customer base. This deal further reinforces A-Bio's position in Asia as a leading biologics contract manufacturer."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.